# Edgewise Therapeutics, Inc.: financial statements, quarterly

EWTX · Nasdaq · CIK 1710072 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ewtx.md) · [Financials](/companies/ewtx/financials.md) · [Filings](/companies/ewtx/filings.md) · [Insiders](/companies/ewtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ewtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [23.8](/filings/0001558370-24-014762.md) | [27.7 d](/filings/0001104659-26-020112.md) | [27.7](/filings/0001558370-25-006857.md) | [30.7](/filings/0001558370-25-010655.md) | [32.2](/filings/0001104659-25-107427.md) | [36.4 d](/filings/0001104659-26-020112.md) | [36.8](/filings/0001104659-26-056713.md) | [33.6](/filings/0001104659-26-091670.md) | [37.5](/filings/0001104659-25-107427.md) | [43.6 d](/filings/0001104659-26-020112.md) | [42.7](/filings/0001104659-26-056713.md) | [47.5](/filings/0001104659-26-091670.md) |
| Operating income | $m | [(29.5)](/filings/0001558370-24-014762.md) | [(33.9) d](/filings/0001104659-26-020112.md) | [(34.8)](/filings/0001558370-25-006857.md) | [(38.1)](/filings/0001558370-25-010655.md) | [(40.4)](/filings/0001104659-25-107427.md) | [(45.5) d](/filings/0001104659-26-020112.md) | [(46.0)](/filings/0001104659-26-056713.md) | [(42.6)](/filings/0001104659-26-091670.md) | [(46.9)](/filings/0001104659-25-107427.md) | [(56.0) d](/filings/0001104659-26-020112.md) | [(54.1)](/filings/0001104659-26-056713.md) | [(61.9)](/filings/0001104659-26-091670.md) |
| Net income | $m | [(25.7)](/filings/0001558370-24-014762.md) | [(30.1) d](/filings/0001104659-26-020112.md) | [(28.5)](/filings/0001104659-25-107427.md) | [(31.5)](/filings/0001104659-25-107427.md) | [(34.1)](/filings/0001104659-25-107427.md) | [(39.7) d](/filings/0001104659-26-020112.md) | [(40.8)](/filings/0001104659-26-091670.md) | [(36.1)](/filings/0001104659-26-091670.md) | [(40.7)](/filings/0001104659-25-107427.md) | [(50.2) d](/filings/0001104659-26-020112.md) | [(49.0)](/filings/0001104659-26-091670.md) | [(57.3)](/filings/0001104659-26-091670.md) |
| Diluted EPS | $ per share | [(0.41)](/filings/0001558370-24-014762.md) | not reported | [(0.33)](/filings/0001558370-25-006857.md) | [(0.34)](/filings/0001558370-25-010655.md) | [(0.36)](/filings/0001104659-25-107427.md) | not reported | [(0.43)](/filings/0001104659-26-056713.md) | [(0.34)](/filings/0001104659-26-091670.md) | [(0.39)](/filings/0001104659-25-107427.md) | not reported | [(0.46)](/filings/0001104659-26-056713.md) | [(0.53)](/filings/0001104659-26-091670.md) |
| Basic EPS | $ per share | [(0.41)](/filings/0001558370-24-014762.md) | not reported | [(0.33)](/filings/0001558370-25-006857.md) | [(0.34)](/filings/0001558370-25-010655.md) | [(0.36)](/filings/0001104659-25-107427.md) | not reported | [(0.43)](/filings/0001104659-26-056713.md) | [(0.34)](/filings/0001104659-26-091670.md) | [(0.39)](/filings/0001104659-25-107427.md) | not reported | [(0.46)](/filings/0001104659-26-056713.md) | [(0.53)](/filings/0001104659-26-091670.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.0](/filings/0001558370-23-018427.md) | [86.1](/filings/0001558370-25-002006.md) | [30.3](/filings/0001544784-24-000056.md) | [43.5](/filings/0001558370-24-011477.md) | [44.8](/filings/0001558370-24-014762.md) | [41.7](/filings/0001104659-26-020112.md) | [49.9](/filings/0001558370-25-006857.md) | [43.4](/filings/0001558370-25-010655.md) | [46.0](/filings/0001104659-25-107427.md) | [61.1](/filings/0001104659-26-091670.md) | [33.2](/filings/0001104659-26-056713.md) | [72.3](/filings/0001104659-26-091670.md) |
| Current assets | $m | [298](/filings/0001558370-23-018427.md) | [327](/filings/0001558370-25-002006.md) | [541](/filings/0001544784-24-000056.md) | [519](/filings/0001558370-24-011477.md) | [499](/filings/0001558370-24-014762.md) | [475](/filings/0001104659-26-020112.md) | [443](/filings/0001558370-25-006857.md) | [603](/filings/0001558370-25-010655.md) | [574](/filings/0001104659-25-107427.md) | [543](/filings/0001104659-26-091670.md) | [510](/filings/0001104659-26-056713.md) | [472](/filings/0001104659-26-091670.md) |
| Total assets | $m | [311](/filings/0001558370-23-018427.md) | [340](/filings/0001558370-25-002006.md) | [554](/filings/0001544784-24-000056.md) | [532](/filings/0001558370-24-011477.md) | [511](/filings/0001558370-24-014762.md) | [487](/filings/0001104659-26-020112.md) | [454](/filings/0001558370-25-006857.md) | [613](/filings/0001558370-25-010655.md) | [583](/filings/0001104659-25-107427.md) | [553](/filings/0001104659-26-091670.md) | [519](/filings/0001104659-26-056713.md) | [480](/filings/0001104659-26-091670.md) |
| Current liabilities | $m | [16.3](/filings/0001558370-23-018427.md) | [16.8](/filings/0001558370-25-002006.md) | [14.6](/filings/0001544784-24-000056.md) | [17.2](/filings/0001558370-24-011477.md) | [19.0](/filings/0001558370-24-014762.md) | [23.9](/filings/0001104659-26-020112.md) | [21.1](/filings/0001558370-25-006857.md) | [20.9](/filings/0001558370-25-010655.md) | [21.6](/filings/0001104659-25-107427.md) | [27.4](/filings/0001104659-26-091670.md) | [22.5](/filings/0001104659-26-056713.md) | [29.0](/filings/0001104659-26-091670.md) |
| Total liabilities | $m | [20.9](/filings/0001558370-23-018427.md) | [21.2](/filings/0001558370-25-002006.md) | [18.9](/filings/0001544784-24-000056.md) | [21.2](/filings/0001558370-24-011477.md) | [22.4](/filings/0001558370-24-014762.md) | [27.6](/filings/0001104659-26-020112.md) | [24.7](/filings/0001558370-25-006857.md) | [24.3](/filings/0001558370-25-010655.md) | [24.8](/filings/0001104659-25-107427.md) | [30.3](/filings/0001104659-26-091670.md) | [25.3](/filings/0001104659-26-056713.md) | [31.6](/filings/0001104659-26-091670.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [290](/filings/0001558370-24-014762.md) | [319](/filings/0001104659-26-020112.md) | [535](/filings/0001104659-25-107427.md) | [510](/filings/0001104659-25-107427.md) | [489](/filings/0001104659-25-107427.md) | [459](/filings/0001104659-26-091670.md) | [430](/filings/0001104659-26-091670.md) | [589](/filings/0001104659-26-091670.md) | [559](/filings/0001104659-25-107427.md) | [522](/filings/0001104659-26-091670.md) | [493](/filings/0001104659-26-091670.md) | [448](/filings/0001104659-26-091670.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.1) d](/filings/0001558370-24-014762.md) | [(26.8) d](/filings/0001104659-26-020112.md) | [(28.6)](/filings/0001558370-25-006857.md) | [(26.1) d](/filings/0001558370-25-010655.md) | [(27.4) d](/filings/0001104659-25-107427.md) | [(27.0) d](/filings/0001104659-26-020112.md) | [(37.9)](/filings/0001104659-26-056713.md) | [(32.6) d](/filings/0001104659-26-091670.md) | [(34.8) d](/filings/0001104659-25-107427.md) | [(38.6) d](/filings/0001104659-26-020112.md) | [(42.5)](/filings/0001104659-26-056713.md) | [(42.5) d](/filings/0001104659-26-091670.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001558370-23-018427.md) | [0.2 d](/filings/0001104659-26-020112.md) | [0.3](/filings/0001544784-24-000056.md) | [0.2 d](/filings/0001558370-24-011477.md) | [0.5 d](/filings/0001104659-25-107427.md) | [0.3 d](/filings/0001104659-26-020112.md) | [0.0](/filings/0001104659-26-056713.md) | [0.1 d](/filings/0001104659-26-091670.md) | [0.1 d](/filings/0001104659-25-107427.md) | [0.1 d](/filings/0001104659-26-020112.md) | [0.3](/filings/0001104659-26-056713.md) | [0.0 d](/filings/0001104659-26-091670.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [51.8](/filings/0001558370-23-018427.md) | [63.3](/filings/0001544784-24-000056.md) | [63.4](/filings/0001558370-24-011477.md) | [63.5](/filings/0001558370-24-014762.md) | [87.6](/filings/0001558370-25-006857.md) | [93.5](/filings/0001558370-25-010655.md) | [93.8](/filings/0001104659-25-107427.md) | [95.1](/filings/0001104659-26-056713.md) | [105](/filings/0001104659-26-091670.md) | [105](/filings/0001104659-25-107427.md) | [107](/filings/0001104659-26-056713.md) | [108](/filings/0001104659-26-091670.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 108,604,129 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-091670.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.